Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia (CLL) drug Venclexta (Roche/Genentech’s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity for Venclexta.

What you will learn in this content:

  • What is U.S. hematologist-oncologists’ awareness of and familiarity with Venclexta, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Venclexta, what are the reasons for prescribing, and how satisfied are they with Venclexta?
  • What promotional messages and activities are Roche/Genentech employing in support of the Venclexta launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Venclexta tracking compared with other recent first-in-class product launches in the oncology market?

Methodology: ~75-100 U.S. hematologist-oncologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten surveyed specialists participate in a 30-minute follow-up qualitative interview.

Related reports: Venclexta Launch Tracking (US) Wave 1, Venclexta Launch Tracking (US) Wave 2, Derzalex/Emplicity Launch Tracking (US) Wave 3

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Emerging Therapies - Venclexta Launch Tracking (US) Wave 3
    • Key Findings
      • Benchmarking Venclexta Launch Success vs. the Competition
        • Unaided Awareness of Venclexta One Year Postlaunch Is Comparable to This Awareness One Month Postlaunch
        • Benchmarking Venclexta's Launch Success vs. the Competition
      • Prescriber and Nonprescriber Profiles
        • Over Half of Prescribers and Even More Nonprescribers Do Not Know Venclexta's Cost
        • Differences Between Venclexta Prescriber and Nonprescriber Profiles
      • Venclexta Awareness and Perceptions
        • Unaided and Aided Awareness of Venclexta
          • Physician Quotes on Perceived Advantages and Disadvantages of Venclexta
          • Awareness of Venclexta
          • Physician Perception of Venclexta's Approved Indications
          • Physician Perception of Venclexta's Administration
          • Awareness of Venclexta's Price
          • Perceived Price of Venclexta
        • Familiarity with Venclexta
          • Sources of Familiarity with Venclexta
            • Venclexta Sources of Familiarity
          • Initial Reaction to and Interest in Venclexta
            • Venclexta Product Profile
            • Initial Reaction to Venclexta
            • Interest in Venclexta
          • Impressions of Venclexta
            • Physician Quotes on Impressions of Venclexta
            • Awareness of Venclexta Profile
            • Venclexta Attributes of Which Hematologist-Oncologists Were Unaware
            • Uniqueness of Venclexta
            • Value of Venclexta Characteristics
            • Mean Value of Venclexta Characteristics
            • Risk/Benefit Perception of Venclexta
          • Prescriber and Nonprescriber Profiles
          • Venclexta Trial and Use
            • Willingness to Prescribe Venclexta
              • Physician Willingness to Prescribe Venclexta to R/R CLL Patients with Del(17p)
              • Impact of Select Attributes on Physician Willingness to Prescribe Venclexta
              • Mean Value of Impact of Select Attributes on Physician Willingness to Prescribe Venclexta
              • Impact of Venclexta's Accelerated Approval Based on ORR Data of Physician Likelihood to Prescribe
            • Number of Patients Currently Receiving Venclexta
              • Venclexta Prescription Rate
              • Patient Share in the Second-Line CLL Del(17p) Setting Now and in Five Months' Time
              • Patient Share in the Third-Line CLL Del(17p) Setting Now and in Five Months' Time
              • Venclexta Discontinuation Rate Among Prescribers
              • Reasons for Discontinuing Venclexta Treatment
              • Treatment Selection Following Venclexta Discontinuation
              • Venclexta Prescribing Practices
              • Treatment Prior to Switching to Venclexta
              • Reasons for Prescribing Venclexta
              • Patient Inquiries Regarding Venclexta in Past Month
              • Physician Quotes on Patient Inquiries Regarding Venclexta
              • Mean Number of Patient Inquiries Regarding Venclexta in Past Month
              • Hematologist-Oncologists' Action Based on Specific Patient Inquiries
              • Primary Obstacles to Prescribing Venclexta to More R/R CLL Patients with Del(17p)
            • Reasons for Not Yet Prescribing Venclexta
              • Lack of Familiarity One of Two Main Reasons for Not Yet Prescribing Venclexta
              • Key Reasons for Not Yet Prescribing Venclexta
            • Anticipated Venclexta Use
              • All Current Nonprescribers Intend to Prescribe Venclexta in the Future
              • Anticipated Venclexta Use Among Nonprescribers
              • Percentage of Second-Line and Third-Line CLL Patients Eligible for Venclexta
              • Potential Displacement of Existing Treatments by Venclexta
            • Venclexta Performance on Key Attributes
              • Over Two-Thirds of Prescribers are Highly Satisfied with Venclexta
              • Overall Level of Satisfaction with Venclexta for Treatment of R/R CLL with Del(17p)
              • Level of Satisfaction with Venclexta on Key Metrics
              • Mean Levels of Satisfaction with Venclexta on Key Attributes
              • Physician Rating of Venclexta on Key Attributes
              • Performance of Venclexta on Key Attributes
          • Effectiveness of Face-to-Face Detailing for Venclexta
            • Venclexta Sales Representative Frequency and Reach
              • Forty Percent of Survey Respondents Never Visited by a Venclexta Representative
              • Last Time of Contact with a Venclexta Representative
            • Satisfaction with Venclexta Sales Representative
              • Majority of Physicians Visited by a Venclexta Sales Rep Highly Satisfied
              • Sales Representative Performance on Key Attributes
              • Sales Representative Mean Performance on Key Attributes
            • Venclexta Message Recall
              • Venclexta Dosing Frequency Discussed More Often One Year Than One Month Postlaunch
              • Topics Discussed by Sales Representatives
              • Positioning of Venclexta Against Other Products
          • Methodology
            • Primary Market Research Methodology
            • Distribution of Hematologist-Oncologists by Region
            • Practice Type
            • Percentage of Professional Time Devoted to Direct Patient Care
            • Years in Clinical Practice
            • Patient Load by Disease Classification
            • Mean Values of Patient Load by Disease Classification
            • CLL Patient Load by Del(17p) Status
            • Primary Practice Location
          • Appendix
            • Key Abbreviations

        Author(s): Dana Gheorghe

        Dana Gheorghe, Ph.D., is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a Ph.D. in cellular biology and biochemistry from the University of Sheffield and a B.Sc./Honors in Molecular Biology from the University of Edinburgh.


        Related Reports

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

        The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the...

        View Details

        Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2020

        The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-y...

        View Details

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Incyte Proprietary Content

        In this project, commissioned by Incyte in February, 2021, we have packaged our published estimates on the epidemiology of NHL & CLL across all the countries in Europe for which we have coverag...

        View Details

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

        In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

        View Details